The lowering of the price target from $70 to $60 by TD Cowen suggests a less optimistic view on Moderna's stock performance, which could lead to a negative short-term impact on the stock price. The Hold rating indicates no immediate buy or sell recommendation, but the reduced target reflects potential challenges or lower expectations.